Rina Maria Gonzalez-Cervantes

Dr. Rina Maria Gonzalez-Cervantes

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Frontiers in Integrative Neuroscience
Verified
Journal Article
Open access
PDF file
AMAugusto J. Montiel-Castro
Augusto J. Montiel-Castro
RGRina Maria Gonzalez-Cervantes
Rina Maria Gonzalez-Cervantes
GBGabriela Bravo-Ruiseco
Gabriela Bravo-Ruiseco
GPGustavo Pacheco-López
Gustavo Pacheco-López
Recent data suggest that the human body is not such a neatly self-sufficient island after all. It is more like a super-complex ecosystem containing trillions of bacteria and other microorganisms that inhabit all our surfaces; skin, mouth, sexual organs, and specially intestines. It has recently become evident that such microbiota, specifically within the gut, can greatly influence many physiological parameters, including cognitive functions, such as learning, memory and decision making processes. Human microbiota is a diverse and dynamic ecosystem, which has evolved in a mutualistic relationship with its host. Ontogenetically, it is vertically inoculated from the mother during birth, established during the first year of life and during lifespan, horizontally transferred among relatives, mates or close community members. This micro-ecosystem serves the host by protecting against pathogens, metabolizing complex lipids and polysaccharides that otherwise would be inaccessible nutrients, neutralizing drugs and carcinogens, modulating intestinal motility, and making visceral perception possible. It is now evident that the bidirectional signaling between the gastrointestinal tract and the brain, mainly through the vagus nerve, the so called ´microbiota-gut-vagus-brain axis,´ is vital for maintaining homeostasis and it may be also involved in the etiology of several metabolic and mental dysfunctions/disorders. Here we review evidence on the ability of the gut microbiota to communicate with the brain and thus modulate behavior, and also elaborate on the ethological and cultural strategies of human and non-human primates to select, transfer and eliminate microorganisms for selecting the commensal profile.

1 May 2014 in Process Biochemistry
Verified
Journal Article
Closed access
JPJaime R. Porras-Domínguez
Jaime R. Porras-Domínguez
ÁÁÁngela Ávila-Fernández
Ángela Ávila-Fernández
MRMaría Elena. Rodríguez-Alegría
María Elena. Rodríguez-Alegría
AMAlfonso Miranda-Molina
Alfonso Miranda-Molina
AEAdelfo Escalante
Adelfo Escalante
ACAgustin Lopez Munguia Canales
Agustin Lopez Munguia Canales

30 June 2023 in Behavioral Sciences
Verified
Journal Article
Open access
PDF file
AMAmapola De Sales Millán
Amapola De Sales Millán
JAJosé Félix Aguirre-Garrido
José Félix Aguirre-Garrido
RGRina Maria Gonzalez-Cervantes
Rina Maria Gonzalez-Cervantes
JVJose Antonio Velázquez-Aragón
Jose Antonio Velázquez-Aragón
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterised by deficits in social interaction and communication, as well as restricted and stereotyped interests. Due of the high prevalence of gastrointestinal disorders in individuals with ASD, researchers have investigated the gut microbiota as a potential contributor to its aetiology. The relationship between the microbiome, gut, and brain (microbiome–gut–brain axis) has been acknowledged as a key factor in modulating brain function and social behaviour, but its connection to the aetiology of ASD is not well understood. Recently, there has been increasing attention on the relationship between the immune system, gastrointestinal disorders and neurological issues in ASD, particularly in relation to the loss of specific species or a decrease in microbial diversity. It focuses on how gut microbiota dysbiosis can affect gut permeability, immune function and microbiota metabolites in ASD. However, a very complete study suggests that dysbiosis is a consequence of the disease and that it has practically no effect on autistic manifestations. This is a review of the relationship between the immune system, microbial diversity and the microbiome–gut–brain axis in the development of autistic symptoms severity and a proposal of a novel role of gut microbiome in ASD, where dysbiosis is a consequence of ASD-related behaviour and where dysbiosis in turn accentuates the autistic manifestations of the patients via the microbiome–gut–brain axis in a feedback circuit.

1 January 2021 in Microbial Pathogenesis
Verified
Journal Article
Closed access
RVRemberto Marcelo Argandoña Valdez
Remberto Marcelo Argandoña Valdez
LXLaurie Ann Ximenez-Fyvie
Laurie Ann Ximenez-Fyvie
KCKarina Sampaio Caiaffa
Karina Sampaio Caiaffa
VSVanessa Rodrigues dos Santos
Vanessa Rodrigues dos Santos
RGRina Maria Gonzalez-Cervantes
Rina Maria Gonzalez-Cervantes
CDCristiane Duque
Cristiane Duque

17 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAmapola De Sales Millán
Amapola De Sales Millán
JAJosé Félix Aguirre-Garrido
José Félix Aguirre-Garrido
RGRina Maria Gonzalez-Cervantes
Rina Maria Gonzalez-Cervantes
JVJose Antonio Velázquez-Aragón
Jose Antonio Velázquez-Aragón
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterised by poor social interaction and communication, as well as restricted and stereotyped interests. Due of the high prevalence of gastrointestinal disorders in individuals with ASD, researchers have investigated the gut microbiota as a potential contributor to its aetiology. The relationship between the microbiome, gut, and brain (microbiome-gut-brain axis) has been acknowledged as a key factor in modulating brain function and social behaviour, but its connection to the aetiology of ASD is not well understood. Recently, there has been increasing attention on the relationship between the immune system, gastrointestinal disorders, and neurological issues in ASD, particularly in relation to the loss of specific species or a decrease in microbial diversity. It focuses on how gut microbiota dysbiosis can affect gut permeability, immune function, and microbiota metabolites in ASD. Although a very complete study suggests that dysbiosis is a consequence of the disease and that it has practically no effect on autistic manifestations. This is a review of the relationship between the immune system, microbial diversity, and the microbiome-gut-brain axis in the development of autistic symptoms severity and, a proposal of a novel role of gut microbiome in ASD, where dysbiosis is a consequence of ASD-related behaviour and where dysbiosis in turn accentuates the autistic manifestations of the patients via microbiome-gut-brain axis in a feedback circuit.

5 December 2025 in Microbiologyopen
Verified
Journal Article
Open access
ISI. Daniel Salinas‐Velarde
I. Daniel Salinas‐Velarde
JDJuan Manuel Donaciano‐Domínguez
Juan Manuel Donaciano‐Domínguez
RORigoberto Oros‐Pantoja
Rigoberto Oros‐Pantoja
JAJosé Félix Aguirre-Garrido
José Félix Aguirre-Garrido
RGRina Maria Gonzalez-Cervantes
Rina Maria Gonzalez-Cervantes
ASAlexandra Estela Soto-Piña
Alexandra Estela Soto-Piña
Gut microbiota (GM) plays a pivotal role in human health and disease, and its alterations have been implicated in various neurological disorders, including Parkinson's disease (PD). Growing evidence reveals correlations between the abundance of specific bacterial taxa and the severity of motor symptoms and intestinal dysfunction in PD. Moreover, bacterial metabolites have been shown to influence α‐synuclein (α‐syn) aggregation and neurodegeneration. This narrative review aims to explore the current understanding of the gut‐brain axis in PD, specifically the connection between GM and α‐syn function in PD experimental models and patients. Several therapeutic strategies aimed at modulating gut microbiota, such as dietary interventions, fecal microbiota transplantation, and targeted bacterial therapies with the goal of alleviating or preventing PD symptoms, are examined. Understanding the mechanisms through which GM influence neurodegeneration, including inflammation, immune modulation, and microbial metabolite production, offers promising avenues for the development of novel therapeutic strategies targeting the microbiome.